Stock listing

Lang & Schwarz:A2PJ5B HUTCHMED (China) Limited Aktie

German listing (Lang & Schwarz) of HUTCHMED (China) Limited · home listing HKEX:13

Follow HUTCHMED (China) Limited into a list and get an email when it puts out news.

Home listing price · HKEX:13

$22.28 HKD +0.84 (+3.9%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:13

Past year -8.9% · daily closes, Oct 16, 2025 – Oct 16, 2026, adjusted for splits
Day range
$21.70 – $22.78 HKDOct 16, 2026
Volume
5.87M sharesOct 16, 2026
52-week range
$15.57 – $25.58 HKDLowest and highest trades, Oct 17, 2025 – Oct 16, 2026
HUTCHMED (China) Limited logo
Ticker
Lang & Schwarz:A2PJ5B
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • HUTCHMED (China) (HKEX:13) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 8:00 AM ET

    Watch Transcript

  • HUTCHMED (China) (HKEX:13) Q4 2025 Earnings Call

    Thu, Mar 05, 2026 · 8:00 AM ET

    Watch Transcript

  • HUTCHMED (China) (HKEX:13) Q3 2025 Earnings Call

    Thu, Aug 07, 2025 · 8:00 PM ET

    Watch Transcript

Latest news

Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2026

Oct 2, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer

Sep 29, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

Sep 28, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

Sep 24, 2026

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Sep 3, 2026

HUTCHMED Reports 2026 Interim Results

Jul 30, 2026

HUTCHMED to Announce 2026 Half-Year Financial Results

Jun 30, 2026

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Apr 29, 2026

All HUTCHMED (China) Limited news

Decks

HUTCHMED (China) Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
10 in the last 12 months · 10 in all · newest Oct 2, 2026 · oldest 2026
Calls
8 calls with a replay · 8 with a transcript · latest Jul 30, 2026
Decks
7 decks · latest Jul 30, 2026

Where HUTCHMED (China) Limited is listed

ListingExchangeCountryCurrency
HKEX:13 和黃醫藥 · Home listingHKEXHong KongHKD
NASDAQ:HCMNASDAQUnited StatesUSD
LSE:HCMLSEUnited KingdomGBX
gettex:H7T2gettexGermanyEUR
LS Exchange:A2PJ5BLS ExchangeGermanyEUR
BOATS:HCMBOATSUnited StatesUSD
Lang & Schwarz:A2PJ5B · This pageLang & SchwarzGermanyEUR
OTC:HMDCFOTCUnited StatesUSD
LSE:0J7GLSEUnited KingdomUSD
Aquis:HCMLAquisUnited KingdomGBX
gettex:H7T1gettexGermanyEUR
AQUIS:HCM.GBAQUISUnited KingdomGBX
Dusseldorf:H7T1DusseldorfGermanyEUR
Dusseldorf:H7T2DusseldorfGermanyEUR
Frankfurt:H7T1FrankfurtGermanyEUR
Frankfurt:H7T2FrankfurtGermanyEUR
Lang & Schwarz:A2AF74Lang & SchwarzGermanyEUR
LS Exchange:A2AF74LS ExchangeGermanyEUR
Munich:H7T2MunichGermanyEUR
Stuttgart:H7T1StuttgartGermanyEUR
Stuttgart:H7T2StuttgartGermanyEUR
Tradegate:H7T1TradegateGermanyEUR
Turquoise:HCMLTurquoiseUnited KingdomGBX

Log in to ask 6ix AI your own questions about HUTCHMED (China) Limited.